Form 4: TransMedics Director Edward Basile Granted 2,134 Restricted Stock Units

TransMedics Group, Inc. Director Edward M. Basile was granted 2,134 restricted stock units (RSUs) on May 22, 2025, increasing his total beneficial ownership to 2,866 shares.

Summary

• Edward M. Basile, a Director of TransMedics Group, Inc. (TMDX), acquired 2,134 restricted stock units (RSUs) on May 22, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The transaction price for these RSUs was $0, which is typical for equity grants of this nature.
• Following this transaction, Mr. Basile's total beneficial ownership in TransMedics Group, Inc. stands at 2,866 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive signal of alignment between the board and shareholder interests, and is a routine compensation practice. While not a major market-moving event, it is generally viewed favorably for corporate governance.

Positives

• The grant of restricted stock units to a director aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• RSU grants are a common and standard form of executive and director compensation, reflecting typical corporate governance practices.

Negatives

• The issuance of RSUs, once vested and converted to common stock, can lead to a minor dilution of existing shareholders' equity, though the impact from individual grants is typically negligible.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• The grant of restricted stock units to a director is a common form of compensation and is considered a related party transaction, as it involves a transaction between the company and a member of its board.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs, but improved alignment of the director's interests with shareholder value creation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

Keywords

TransMedics Group Inc., TMDX, SEC Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership, Edward M. Basile